Drug: Crizotinib for Lung Cancer

CrizotinibCrizotinib FDA Approved

Among cancer-related deaths in the United States, lung cancer is the leading cause. FDA has approved the use of Xalkori (crizotinib) for treating patients with non-small cell lung cancer (NSCLC). It is the only FDA approved for patients with ROS-1 positive NSCLC. It is generally recommended for those with advanced NSCLC and has not received treatment before.

How it Works?

Crizotinib works to shrink or slow the growth of tumors among the patients by targeting a specific protein. Crizotinib helps in curing people with NSCLC that has spread to other parts of the body. It is an oral medication that blocks the activity of ROS-1 protein in tumors. This effect may help in preventing NSCLC from further growth and spread. FDA has also granted Xalkori use application breakthrough therapy designation and priority review status.

Side Effects of Crizotinib:

The common side effects include:

  • Nausea or vomiting
  • Itching
  • Vision problems
  • Swelling
  • Diarrhea
  • Constipation

It may cause serious side effects such as:

  • Liver problems
  • Lung problems
  • Abnormal heartbeats

Precautions to be Taken

Before you start intake of this medication, you should inform your healthcare provider if you are pregnant or plan to become pregnant. If you have heart, liver or kidney problems or any other medical conditions, all medical history should be communicated to your doctor. Also, tell your healthcare provider about the medicines you take such as prescription drugs, over-the-counter medicines or even vitamins.

If you have any severe problem with intake of Crizotinib, you should contact your healthcare provider immediately.

Share your thoughts on the story in the comments.


All information provided in this blog is for informational purposes only and is not a substitute for medical advice. You should not start taking it before confirmation with your doctor.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.